Creative Biolabs: Continually Extending Capabilities in Conjugates

USA – April 19, 2022 /MarketersMEDIA/ —

The ADC concept was first proposed in 1913 by Nobel Laureate in Physiology and Medicine, Paul Ehrlich, and it has a history of more than a century, with a current surge of interest in R&D. Facing the increasing demand for ADC development, Creative Biolabs has strengthened its capabilities, recruiting more talented scientists with rich practical experience and upgrading service and product coverage. 

One of the health issues irritating the entire globe is bacteria infection, against which using antibodies as drugs has a longer history than antibiotics. AAC (antibody-antibiotic conjugate), an innovative form of ADC that has evolved as a new tool against bacteria infection with superior specificity and precision, which, most important of all, can greatly relieve the problem of drug resistance. 

“Our conjugate service range extends,” noted a scientist, “and now we can help develop conjugates to support antibiotic drug studies.”

The core of AAC development is in line with that of an ADC, and choosing suitable linker matters. Owning specialties in ADC linker design and synthesis, Creative Biolabs makes sure that the linker used for AAC development will have high compatibility with the half-life of antibody, meanwhile preserving stability at physiologically relevant pH values to avoid pre-mature drug release.

The real strengths in conjugation enable Creative Biolabs a widespread service scope, extending to ABC, AOC, and some other conjugate formats that are under intensive studies. Also, facing the increasing number of inquiries on ADC research-use substances, e.g., antibodies, ADC toxins, and anti-drug antibodies, Creative Biolabs has established a product center storing substances that are prepared and ready for instant delivery.

“Our product scope expands and output grows,” added the scientist, “as we have updated our exclusive DrugLnk platform.”

Of note, the proprietary synthesis platform is the mainstream power in producing ADC toxins, linkers, and drug-linker complexes.

• Toxins: auristatins, maytansinoids, calicheamicins, and amatoxins, which are characterized by over 95% purity by LC-MS and 1HNMR.
• Linkers: cleavable linkers (pH-sensitive linkers, disulfide linkers, peptide linkers, and β-glucuronide linkers), non-cleavable linkers, and intermediate linker modules.
• Pre-assembled drug-linker complexes: Vc-MMAE, Cys-mcMMAD, DBCO-PEG4-MMAF, etc.

“All of the listed products are well-prepared to ensure support customers’ projects efficiently. As a CRO, Creative Biolabs is always willing to offer one-stop custom solutions if what is needed is not covered by our current product list.”

Browse https://www.creative-biolabs.com/adc/ to learn more about Creative Biolabs’ ability regarding ADC.

Profile

Creative Biolabs has positioned itself as a leader in the development of customized immunotherapy and antibody-drug conjugates (ADCs), providing a one-stop shop for all components of ADC research and development, from antigen selection through antibody production/optimization, payload-linker synthesis, ADC conjugation, and various stages of ADC characterization and pre-clinical evaluation.

Contact Info:
Name: Candy Swift
Email: Send Email
Organization: Creative Biolabs
Website: https://www.creative-biolabs.com/adc/

Release ID: 89073411

If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us. We will respond and rectify the situation in the next 8 hours.